Profile data is unavailable for this security.
About the company
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
- Revenue in INR (TTM)22.19bn
- Net income in INR5.02bn
- Incorporated1950
- Employees1.70k
- LocationPfizer LtdPfizer Centre, 5, Patel EstateOff S.V. Road, Jogeshwari (W)MUMBAI 400051IndiaIND
- Phone+91 2 266932000
- Fax+91 2 266932444
- Websitehttp://www.pfizerindia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 102.53bn | 407.00 | -- | -- | -- | 96.11 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Glenmark Life Sciences Ltd | 23.68bn | 5.19bn | 102.87bn | 1.82k | 19.82 | -- | 18.06 | 4.34 | 42.36 | 42.36 | 193.15 | -- | -- | -- | -- | 12,982,110.00 | -- | -- | -- | -- | 55.92 | -- | 21.93 | -- | -- | 538.47 | -- | -- | 1.79 | -- | 11.52 | -- | -- | -- |
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 107.85bn | 1.03k | 281.08 | -- | 18.40 | 1.63 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
| Eris Lifesciences Ltd | 18.61bn | 3.86bn | 119.93bn | 3.55k | 31.08 | -- | 22.10 | 6.44 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
| Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 131.10bn | 947.00 | 94.12 | -- | 84.73 | 10.95 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
| Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 162.27bn | 1.17k | 43.73 | -- | 38.63 | 13.90 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
| Concord Biotech Ltd | 9.71bn | 3.05bn | 165.65bn | -- | 55.06 | -- | 46.19 | 17.07 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
| Natco Pharma Ltd. | 38.28bn | 12.78bn | 180.13bn | 3.98k | 14.20 | -- | 12.42 | 4.71 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
| Piramal Pharma Ltd | 77.82bn | -333.40m | 186.23bn | 6.30k | -- | -- | 26.78 | 2.39 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
| Piramal Enterprises Ltd | 79.98bn | -20.16bn | 187.07bn | 12.22k | -- | -- | -- | 2.34 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
| Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 187.15bn | 14.59k | 31.71 | -- | 21.34 | 3.06 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
| Sanofi India Ltd | 28.51bn | 6.03bn | 189.32bn | 3.53k | 31.40 | 18.65 | 29.47 | 6.64 | 261.78 | 261.78 | 1,237.96 | 440.80 | 1.51 | 2.24 | 21.86 | -- | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.69 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 58.18 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Pfizer Ltd | 22.19bn | 5.02bn | 189.55bn | 1.70k | 37.75 | -- | 32.85 | 8.54 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
| Laurus Labs Ltd | 49.82bn | 1.88bn | 231.78bn | 5.75k | 123.73 | -- | 40.70 | 4.65 | 3.48 | 3.48 | 92.17 | -- | -- | -- | -- | 8,659,934.00 | -- | 11.78 | -- | 19.75 | 51.73 | 48.41 | 4.02 | 14.16 | -- | 2.50 | -- | 12.37 | 22.39 | 23.90 | -4.52 | 36.36 | 20.42 | 31.95 |
| Ajanta Pharma Ltd | 40.36bn | 7.36bn | 263.33bn | 7.71k | 35.91 | -- | 30.27 | 6.52 | 58.24 | 58.24 | 319.08 | -- | -- | -- | -- | 5,233,334.00 | -- | 16.13 | -- | 19.52 | 74.16 | 74.01 | 18.23 | 19.22 | -- | 100.64 | -- | 15.93 | 12.02 | 11.92 | -17.50 | 4.64 | -7.86 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 277.48bn | 5.10k | 54.79 | -- | 43.12 | 8.20 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
Data as of Apr 23 2024. Currency figures normalised to Pfizer Ltd's reporting currency: Indian Rupee INR
16.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 3.29m | 7.20% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 1.71m | 3.75% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 642.34k | 1.40% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024 | 467.88k | 1.02% |
| DSP Asset Managers Pvt. Ltd.as of 31 Mar 2024 | 274.74k | 0.60% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Mar 2024 | 260.51k | 0.57% |
| Goldman Sachs Asset Management LPas of 31 Jan 2024 | 258.52k | 0.57% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 226.14k | 0.49% |
| SBI Funds Management Ltd.as of 31 Mar 2024 | 206.03k | 0.45% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 Mar 2024 | 119.94k | 0.26% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
